| 12.08 -0.47 (-3.75%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.7 | 1-year : | 18.34 |
| Resists | First : | 13.44 | Second : | 15.7 |
| Pivot price | 12.3  |
|||
| Supports | First : | 11.6 | Second : | 10.46 |
| MAs | MA(5) : | 12.42 |
MA(20) : | 11.98 |
| MA(100) : | 11.04 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 66.9 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 14.43 | Low : | 4.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MNMD ] has closed above bottom band by 33.0%. Bollinger Bands are 42.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.79 - 12.87 | 12.87 - 12.95 |
| Low: | 11.82 - 11.9 | 11.9 - 11.99 |
| Close: | 11.93 - 12.07 | 12.07 - 12.21 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mon, 15 Dec 2025
MindMed Announces New Employee Inducement Grant - Business Wire
Wed, 10 Dec 2025
Diadema Partners LP Makes New Investment in Mind Medicine (MindMed) Inc. $MNMD - MarketBeat
Tue, 09 Dec 2025
Marshall Wace LLP Has $22.20 Million Holdings in Mind Medicine (MindMed) Inc. $MNMD - MarketBeat
Fri, 28 Nov 2025
Mind Medicine (MNMD) Reports Wider Loss and Major Equity Raise, How Will Capital Shape Its R&D Ambitions? - Sahm
Wed, 29 Oct 2025
Mind Medicine Inc. Announces Proposed Public Offering - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 41.7 (%) |
| Shares Short | 12,350 (K) |
| Shares Short P.Month | 11,840 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -85.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -6.11 |
| PEG Ratio | 0 |
| Price to Book value | 7.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|